Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Stock Position Lessened by GAMMA Investing LLC

GAMMA Investing LLC reduced its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 41.1% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,390 shares of the company’s stock after selling 3,068 shares during the quarter. GAMMA Investing LLC’s holdings in Teva Pharmaceutical Industries were worth $67,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in TEVA. Jones Financial Companies Lllp increased its stake in shares of Teva Pharmaceutical Industries by 145.4% during the fourth quarter. Jones Financial Companies Lllp now owns 8,592 shares of the company’s stock valued at $189,000 after acquiring an additional 5,091 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 14.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,924 shares of the company’s stock valued at $22,677,000 after buying an additional 129,749 shares in the last quarter. Assetmark Inc. lifted its position in shares of Teva Pharmaceutical Industries by 1,370.3% in the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock worth $115,000 after purchasing an additional 4,851 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $38,914,000. Finally, Callan Family Office LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth about $207,000. 54.05% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have commented on TEVA shares. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. Truist Financial began coverage on Teva Pharmaceutical Industries in a report on Wednesday, May 28th. They issued a “buy” rating and a $25.00 target price on the stock. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and raised their price target for the company from $21.00 to $23.00 in a report on Monday, May 12th. Hsbc Global Res upgraded shares of Teva Pharmaceutical Industries to a “strong-buy” rating in a research report on Monday, April 28th. Finally, Bank of America lifted their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a “buy” rating in a research note on Thursday, May 8th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $24.13.

Teva Pharmaceutical Industries Trading Down 1.2%

NYSE:TEVA opened at $16.65 on Wednesday. The company has a market cap of $19.10 billion, a P/E ratio of -14.48, a price-to-earnings-growth ratio of 0.86 and a beta of 0.60. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $22.80. The business has a 50 day moving average price of $17.05 and a two-hundred day moving average price of $17.28. The company has a quick ratio of 0.74, a current ratio of 1.03 and a debt-to-equity ratio of 2.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, topping the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.99 billion. During the same quarter in the prior year, the company posted $0.48 earnings per share. The firm’s revenue was up 1.9% on a year-over-year basis. As a group, analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Matthew Shields sold 6,206 shares of the firm’s stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total value of $105,626.12. Following the completion of the transaction, the executive vice president directly owned 9,989 shares in the company, valued at $170,012.78. This trade represents a 38.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.55% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.